TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET

Overview

1. 1981-2015historic

   Target discovery and antibody development

   TROP2 identified on trophoblasts (1981); overexpression across epithelial cancers established in the 2000s. Immunomedics humanises the RS7 antibody and conjugates SN-38 (IMMU-132) with a moderately stable, hydrolysable linker designed to release payload in the tumour microenvironment.

   Hide era· 1 record

   TROP2
2. 2020-2021historic

   Sacituzumab govitecan proves the target

   ASCENT: OS 12.1 vs 6.7 months in pretreated metastatic TNBC; accelerated then full approval. Gilead acquires Immunomedics for $21B. Benefit irrespective of TROP2 IHC, so no companion diagnostic is required.

   Show era· 3 records
3. 2023-2025current

   Second entrant: datopotamab deruxtecan

   Datopotamab deruxtecan carries the DXd payload at DAR 4 on a different anti-TROP2 antibody. TROPION-Breast01 (HR+, PFS only) and TROPION-Lung01 (mixed) produce narrow approvals (HR+ breast 2025; EGFR-mutant NSCLC 2025). Stomatitis and ocular toxicity define its profile versus sacituzumab's neutropenia and diarrhoea. Sacituzumab expands to HR+ (TROPiCS-02) but loses its urothelial indication.

   Show era· 3 records
4. 2025-2026current

   First line: three positive phase 3 trials

   ASCENT-03 (sacituzumab, PD-1-ineligible), ASCENT-04 (sacituzumab + pembrolizumab, PD-L1+), and TROPION-Breast02 (Dato-DXd, PD-1-ineligible, first OS benefit) all read out positive, with FDA approvals in Q2 2026. TROP2 ADCs displace chemotherapy in first-line metastatic TNBC. TROPION-Breast05 (Dato-DXd + durvalumab) is pending.

   Hide era· 4 records

   ASCENT-03ASCENT-04 / KEYNOTE-D19TROPION-Breast02TROPION-Breast05

   Trial outcomes

   ASCENT-03

   In plain words

   What these results mean for people, not percentages

   558 randomised

   Progression-free survival (BICR)primarysurrogate endpoint

   • Median 9.7 vs 6.9 months with Sacituzumab govitecan compared with Chemotherapy (TPC); about 2.8 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62, likely range 0.5 to 0.77).

   Objective response rateresponse endpoint

   • 48 vs 44 out of 100 had their tumour shrink with Sacituzumab govitecan compared with Chemotherapy (TPC); 4 more per 100.
   • Roughly one extra person helped for every 25 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.

   Overall survivalsurvival endpoint

   • Numbers are not recorded here for this endpoint. Sacituzumab govitecan: Immature at the primary analysis; crossover to sacituzumab permitted on progression.; Chemotherapy (TPC).

   Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

   Pictograms, table and sources on the trial page

   ASCENT-04 / KEYNOTE-D19

   In plain words

   What these results mean for people, not percentages

   443 enrolled

   Progression-free survival (BICR)primarysurrogate endpoint

   • Median 11.2 vs 7.8 months with Sacituzumab govitecan + pembrolizumab compared with Chemotherapy + pembrolizumab; about 3.4 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 35 percent lower chance of the event at any given time (hazard ratio 0.65, likely range 0.51 to 0.84).

   Objective response rateresponse endpoint

   • 60 vs 53 out of 100 had their tumour shrink with Sacituzumab govitecan + pembrolizumab compared with Chemotherapy + pembrolizumab; 7 more per 100.
   • Roughly one extra person helped for every 14 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.

   Overall survivalsurvival endpoint

   • Numbers are not recorded here for this endpoint. Sacituzumab govitecan + pembrolizumab: Immature; PFS2 favoured the ADC arm in the ASCO 2026 update.; Chemotherapy + pembrolizumab.

   Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

   Pictograms, table and sources on the trial page

   TROPION-Breast02

   In plain words

   What these results mean for people, not percentages

   644 enrolled

   Progression-free survival (BICR)primarysurrogate endpoint

   • Median 10.8 vs 5.6 months with Datopotamab deruxtecan compared with Chemotherapy (ICC); about 5.2 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 43 percent lower chance of the event at any given time (hazard ratio 0.57, likely range 0.47 to 0.69).

   Overall survivalprimarysurvival endpoint

   • Median 23.7 vs 18.7 months with Datopotamab deruxtecan compared with Chemotherapy (ICC); about 5 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 21 percent lower chance of the event at any given time (hazard ratio 0.79, likely range 0.64 to 0.98).

   Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

   Pictograms, table and sources on the trial page

5. 2024-2027emerging

   Third entrant: sacituzumab tirumotecan and the Merck programme

   Kelun's sac-TMT, with a belotecan-derived payload and a more stable linker, is approved in China (2024) and licensed to Merck, which is running >10 phase 3 TroFuse trials across TNBC, HR+ breast, NSCLC, endometrial, and cervical cancer, often with pembrolizumab. FDA priority voucher July 2026; US approval expected to follow positive first-line TNBC data.

   Show era· 3 records
6. 2026-2029emerging

   Unsolved: selection, sequencing, resistance

   IHC does not predict benefit. Cross-resistance among TOP1 payloads limits sequencing (T-DXd → sacituzumab or vice versa). TROP2 PET tracers (89Zr-antibody, 68Ga/18F-nanobody) enter phase 1 to map antigen, guide choice, and monitor loss. ctDNA and SLFN11/TOP1 biomarkers for payload resistance are under study.

   Show era· 4 records
7. 2027+speculative45% to 70%likely

   Next generation: bispecific and next-payload TROP2 ADCs

   Nectin-4×TROP2 bispecific ADCs (AK146D1, AVZO-103), TROP2 ADCs with non-TOP1 or dual payloads, TROP2-directed radioconjugates, and TROP2 CAR-T. The class moves into early-stage disease (neoadjuvant/post-neoadjuvant TNBC) and into lung, gastric, and endometrial cancer. A TROP2 PET-guided, payload-switching treatment algorithm is the field's implicit goal.

   Show era· 5 records

Every era's records, trial outcomes and papers, and every watch item, as JSON.